Artrya (ASX:AYA) - MD John Barrington (left) and Executive Director John Konstantopoulos (right)
MD John Barrington (left) and Executive Director John Konstantopoulos (right)
Source: Artrya
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Artrya (AYA) receives regulatory approval for its Salix Coronary Anatomy (SCA) product in the United Kingdom from the European Notified Body (BSI)
  • The BSI found that the company’s Salix V2.0 software had met or exceeded all regulatory requirements and has recommended the software for marketing into the UK
  • With the new approval, Artrya is now able to approach hospitals as part of its four-year contract with the SCA product to finalise arrangements for the product roll out
  • Shares in Artrya end the day 3.03 per cent in the red to close at 64 cents

Australian medical technology company Artrya (AYA) has received regulatory approval for its Salix Coronary Anatomy (SCA) product in the United Kingdom.

The European Notified Body (BSI) informed the company that the assessment for UKCA Class 2 certification is complete and the software had met or exceeded all regulatory requirements.

The recommendation by the BSI is certification of the Salix V2.0 software for marketing into the UK.

Managing Director and CEO John Barrington said UK regulatory approval was a landmark
moment for the company.

“Our business activities in the UK are advanced and Artrya is well positioned to take advantage of the regulatory approval in this significant market,” he said.

“This is Artrya’s biggest market opportunity to date and we aim to take full advantage of it.”

Currently, the company has a four-year contract in place to supply 1250 National Health Service (NHS) Trust Hospitals throughout the UK with the SCA product.

With the new approval, Artrya is now able to approach these hospitals to finalise arrangements for the product roll out.

The company said other business development activities in the UK are well advanced for use of the SCA product within clinical practices outside of the NHS network.

Shares in Artrya ended the day 3.03 per cent in the red to close at 64 cents.

AYA by the numbers
More From The Market Online
Landscape of the Northern Territory

New Frontier dives into heavy rare earths market at Harts Range

New Frontier Minerals Ltd has completed analysis of rock chip samples at its Harts Range project…
The Market Online Video

ASX Market Open: Markets catch flack from China-US trade war back and forth | April 9, 2025

The local bourse will open as much as 2% lower this Wednesday morning as Australian markets continue to track the escalating China-U.S.
Trees in Namibia

Golden Deeps finds high grade gallium at Nosib – and expansion is on the card

Golden Deeps Ltd has found high grade gallium and various other commodities through a historical review…
The Market Online Video

ASX Market Close: IT stocks leads index higher | April 8, 2025

The ASX200 closed up 2.27% at 7,510 points.